Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
clinical trials
drugs
3
×
life sciences
national blog main
rna interference
3
×
aminolevulinic acid
fda
givosiran
patisiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
barry greene
biotech
boston university
dan ollendorf
hereditary transthyretin amyloidosis
inotersen
john berk
mary o'donnell
national top stories
new york blog main
new york top stories
onpattro
paul matteis
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
stifel financial
tafamidis
the amyloidosis foundation
the institute for clinical and economic review
What
alnylam
medicine
3
×
rna
ago
drug
fda
interference
pharmaceuticals
rnai
second
seek
speedy
approval
approve
awaits
biological
cleared
crossed
data
decades
decision
discovered
far
fingers
friday
historic
indicated
market
nasdaq
new
nod
ok
patients
quick
time
trick
uses
weeks
won’t
Language
Current search:
drugs
×
medicine
×
" rna interference "
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision